Benefits
Mast Cell Stabilization
Luteolin is a potent inhibitor of mast cell degranulation — mast cells release histamine, tryptase, and inflammatory mediators in allergies and mast cell activation syndrome (MCAS). Theoharides 2015 and others establish luteolin as foundational MCAS supplement. Often combined with quercetin.
Neuroinflammation Reduction
Microglial activation drives neuroinflammation in Alzheimer's, autism, and chronic neurological conditions. Luteolin reduces microglial activation and pro-inflammatory cytokines in animal models. Theoretical autism spectrum applications.
Cancer Chemoprevention Research
Extensive in vitro evidence: induces apoptosis, inhibits angiogenesis, reduces metastasis in cancer cell lines. Animal models show tumor growth reduction. Human clinical translation limited.
Cardiovascular Anti-Atherosclerotic Effects
Reduces LDL oxidation, vascular inflammation, and adhesion molecule expression — anti-atherosclerotic mechanisms. Modest cholesterol effects. Mostly mechanistic and animal evidence.
Senolytic Activity (Adjunctive)
Identified along with fisetin in Mayo Clinic flavonoid screening as having senolytic activity, though less potent than fisetin. Component of multi-flavonoid longevity stacks.
Mechanism of action
Mast Cell Stabilization
Luteolin inhibits mast cell degranulation by stabilizing mast cell membranes and inhibiting calcium-dependent degranulation pathways. Reduces histamine, tryptase, and cytokine release. Foundational mechanism for allergy/MCAS application.
NF-κB Pathway Inhibition
Inhibits NF-κB activation — reducing pro-inflammatory gene expression (TNF-alpha, IL-6, IL-1β, COX-2, iNOS). Broad anti-inflammatory profile.
Microglial Modulation (Brain)
Reduces activated microglia (the brain's immune cells) — relevant for neuroinflammation in chronic neurological conditions. Crosses blood-brain barrier.
Histamine N-Methyltransferase Effects
Modest inhibition of histamine breakdown enzymes balanced against mast cell stabilization — net effect depends on context. Generally anti-allergic clinically.
Clinical trials
Open-label trial of luteolin formulation (with quercetin and rutin in liposomal form) in children with ASD over 26 weeks.
37 children with ASD.
Open-label improvements in adaptive behaviors, communication, social interaction, and GI symptoms. CRITICAL CAVEAT: open-label, no placebo control; subsequent placebo-controlled trials less robust. Theoretical mechanism (neuroinflammation reduction) has gained interest.
Multiple papers and case series by Theoharides et al. on luteolin as mast cell stabilizer for MCAS, chronic urticaria, related conditions.
MCAS patients, chronic urticaria patients.
Modest symptom improvements in mast cell-related conditions. Open-label/observational primarily; rigorous RCTs limited. Foundational supplement in functional medicine MCAS protocols.